147 related articles for article (PubMed ID: 6434315)
21. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
22. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
[TBL] [Abstract][Full Text] [Related]
23. Megestrol acetate: a new role in the treatment of metastatic breast cancer.
Allegra JC
Semin Hematol; 1987 Apr; 24(2 Suppl 1):45-7. PubMed ID: 3589707
[TBL] [Abstract][Full Text] [Related]
24. [Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies].
Wander HE; Blossey HC; Nagel GA; Emrich D
Klin Wochenschr; 1985 Apr; 63(7):312-8. PubMed ID: 2987601
[TBL] [Abstract][Full Text] [Related]
25. Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients--short and long term endocrine effects.
Canobbio L; Galligioni E; Gasparini G; Fassio T; Crivellari D; Villalta D; Santini G; Monfardini S; Boccardo F
Breast Cancer Res Treat; 1987 Nov; 10(2):201-4. PubMed ID: 3427228
[TBL] [Abstract][Full Text] [Related]
26. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.
Paterson AH; Hanson J; Pritchard KI; Sansregret E; Dahrouge S; McDermot RS; Fine S; White DF; Trudeau M; Stewart DJ
Semin Oncol; 1990 Dec; 17(6 Suppl 9):52-62. PubMed ID: 2259927
[TBL] [Abstract][Full Text] [Related]
27. Megestrol acetate may stimulate the production of insulin-like growth factor 1 in breast tissues of women with breast cancer.
Fahlén M; Löfgren L; von Schoultz E; Naessén S; Carlström K; Söderqvist G
Horm Mol Biol Clin Investig; 2013 Jun; 13(3):51-4. PubMed ID: 25436713
[TBL] [Abstract][Full Text] [Related]
28. Results of curettage for postmenopausal vaginal bleeding in women treated with tamoxifen and megestrol acetate for progressive metastatic breast carcinoma.
Logmans A; Mous HV; Bontenbal M; Beerman H; van Lent M
Eur J Obstet Gynecol Reprod Biol; 1994 Sep; 56(3):173-6. PubMed ID: 7821489
[TBL] [Abstract][Full Text] [Related]
29. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen.
Ross MB; Buzdar AU; Blumenschein GR
Cancer; 1982 Feb; 49(3):413-7. PubMed ID: 6174195
[TBL] [Abstract][Full Text] [Related]
31. Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.
Ettinger DS; Allegra J; Bertino JR; Bonomi P; Browder H; Byrne P; Carpenter J; Catalano R; Creech R; Dana B
Semin Oncol; 1986 Dec; 13(4 Suppl 4):9-14. PubMed ID: 3026052
[TBL] [Abstract][Full Text] [Related]
32. Plasma hormones in patients with advanced breast cancer treated with tamoxifen.
Golder MP; Phillips ME; Fahmy DR; Preece PE; Jones V; Henk JM; Griffiths K
Eur J Cancer (1965); 1976 Sep; 12(9):719-23. PubMed ID: 971694
[No Abstract] [Full Text] [Related]
33. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
[TBL] [Abstract][Full Text] [Related]
34. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Pannuti F; Martoni A; Farabegoli G; Piana E
Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
[TBL] [Abstract][Full Text] [Related]
35. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
Sherman BM; Chapler FK; Crickard K; Wycoff D
J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
[TBL] [Abstract][Full Text] [Related]
36. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
Robertson JF; Walker KJ; Nicholson RI; Blamey RW
Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
[TBL] [Abstract][Full Text] [Related]
37. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
[TBL] [Abstract][Full Text] [Related]
38. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB
Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310
[TBL] [Abstract][Full Text] [Related]
39. [Serum levels of prolactin, estradiol, testosterone and sex hormone-binding globulin in women with breast cancer treated with cytostatics and anti-estrogens].
Grodecka-Gazdecka S; Baron J
Ginekol Pol; 1986 Dec; 57(12):778-83. PubMed ID: 3570023
[No Abstract] [Full Text] [Related]
40. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
Geisler J; Ekse D; Hösch S; Lønning PE
J Steroid Biochem Mol Biol; 1995 Nov; 55(2):193-5. PubMed ID: 7495698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
